Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 1 2

Status

Completed 2Active not recruiting 2

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Thoracic 2Other solid neoplasm 2

Conditions

Small Cell Lung Carcinoma 2Advanced Solid Tumors 1Advanced Solid Tumor 1

Interventions

pembrolizumab 302Carboplatin 155Nivolumab 154Cisplatin 139Cyclophosphamide 130Paclitaxel 127Magnetic Resonance Spectroscopy 98Specimen Handling 95Radiotherapy 90Gemcitabine 87Dexamethasone 83Biopsy 81Ipilimumab 78Docetaxel 75Doxorubicin 75Rituximab 69Etoposide 67atezolizumab 61durvalumab 60Lenalidomide 59Radiation 59Pemetrexed 58Taxes 57Bevacizumab 54Prednisone 54fludarabine 54olaparib 53Cytarabine 49Vincristine 49Fluorouracil 48

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Has results × PM 01183 × 1 year × Clear all
NCT05091567 2026-03-10

IMforte

Hoffmann-La Roche

Phase 3 Active not recruiting
660 enrolled 23 charts 1 FDA
Thoracic

Small Cell Lung Carcinoma

NCT05740566 2026-01-05

DeLLphi-304

Amgen

Phase 3 Active not recruiting
509 enrolled 11 charts 1 FDA
Thoracic

Small Cell Lung Carcinoma

NCT05072106 2025-09-16

Study to Evaluate the Effect of Bosentan on the Pharmacokinetics of Lurbinectedin in Patients With Advanced Solid Tumors

PharmaMar

Phase 1 Completed
11 enrolled 26 charts
Other solid neoplasm

Advanced Solid Tumor

NCT05063318 2025-09-02

Clinical Trial of Lurbinectedin (PM01183) in Patients With Advanced Solid Tumors

PharmaMar

Phase 1 Completed
14 enrolled 20 charts
Other solid neoplasm

Advanced Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡